Recently, the pre-planned interim analysis of the J-ALEX trial, demonstrated the superiority of alectinib to crizotinib in untreated ALK-rearranged NSCLC patients (median PFS not reached versus 10.2 months; HR 0.34; p < 0.0001) [19]. This evidence concerns the gene ALK and non-small cell lung carcinoma.